Updated Jul 16, 2026
Inrig Jula has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.75M.
Jula Inrig is the Chief Medical Officer at Travere Therapeutics, Inc., a biopharmaceutical company focused on therapies for rare kidney, liver, and metabolic diseases. She has been involved in the development of therapies aimed at addressing significant unmet medical needs in these areas.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-22 | TVTX | Travere Therapeutics, Inc. | G — Bona-fide gift | 468 | $0.00 | |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 311 | $43.95 | $14K |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 2.2K | $46.65 | $101K |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | M — Option exercise | 4.2K | $0.00 | |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 20.0K | $45.00 | $900K |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | M — Option exercise | 20.0K | $22.40 | $448K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 1.0K | $42.61 | $43K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 7.2K | $41.93 | $303K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | A — Grant or award | 14.0K | $0.00 | |
| 2026-02-05 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale [10b5-1] | 232 | $32.85 | $8K |
| 2026-02-05 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.5K | $32.11 | $50K |
| 2026-02-04 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 7.0K | $32.12 | $223K |
| 2026-02-04 | TVTX | Travere Therapeutics, Inc. | A — Grant or award | 28.1K | $0.00 | |
| 2026-01-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale [10b5-1] | 445 | $37.75 | $17K |
| 2026-01-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.0K | $40.18 | $82K |
| 2025-07-01 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 815 | $14.65 | $12K |
Jula Inrig is the Chief Medical Officer at Travere Therapeutics, Inc., a biopharmaceutical company focused on therapies for rare kidney, liver, and metabolic diseases. She has been involved in the development of therapies aimed at addressing significant unmet medical needs in these areas.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 11 open-market sales ($1.75M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Inrig Jula profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.